Redeye reiterates a base case fair value of SEK 2.5 following the 2019 year-end earnings report. The clinical BI-1206 NHL program seems to run somewhat slower than our expectations, but on the positive side, the antibody manufacturing unit develops better. Short-term catalysts for the stock are milestone payments from Pfizer that could exceed SEK 50m (total).